Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

NCT04628767 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04628767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04628767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Recruiting
Start date
November 12, 2021
Completion date
September 30, 2027
Enrollment
131 (estimated)
Sites
257

Conditions

As the registry lists them; a condition with its own page is linked.

renal pelvis and ureter urothelial carcinoma